F
Faruk Alagol
Researcher at Koç University
Publications - 59
Citations - 937
Faruk Alagol is an academic researcher from Koç University. The author has contributed to research in topics: Thyroid & Thyroid carcinoma. The author has an hindex of 18, co-authored 58 publications receiving 879 citations. Previous affiliations of Faruk Alagol include Istanbul University.
Papers
More filters
Journal ArticleDOI
Sunlight exposure and vitamin D deficiency in Turkish women
TL;DR: In this article, the efficiency of vitamin D synthesis in 48 premenopausal women (14-44 years) in relation to three different types of dressing in summer was investigated, and the results indicated that sun exposure of skin areas of hands and face may partially provide vitamin D, but may not be enough to eliminate vitamin D deficiency.
Journal ArticleDOI
Dual ectopic thyroid: report of a case
TL;DR: A case of dual ectopic thyroid in the lingual and infrahyoid areas in a 20-year-old female patient with no thyroid gland in its normal anatomical location is reported and the importance of thyroid scanning in the evaluation of anterior midline neck swellings is discussed.
Journal Article
Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
TL;DR: Technetium-99m-tetrofosmin and 201Tl imaging are highly sensitive for detecting differentiated thyroid carcinoma metastases and do not require prior withdrawal of thyroid hormone suppressive therapy.
Journal ArticleDOI
Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term
Ayse Kubat Uzum,Serpil Salman,Aysegul Telci,Harika Boztepe,Refik Tanakol,Faruk Alagol,Nese Ozbey +6 more
TL;DR: In this paper, the effect of vitamin D replacement therapy on serum FGF23 concentrations in vitamin Ddeficient women and to compare the FGF-23 concentrations of healthy subjects and patients with genetically determined hypophosphatemic rachitis was determined.
Journal ArticleDOI
Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
TL;DR: Patients with PTC traditionally categorized as having low risk during their first 9 to 12 months after primary treatment have a greater risk of R-LTFU if their postablative STg is ≥0.3 ng/mL, or they have positive anti-Tg, even at this early stage.